**Correction to: BMC Nephrol (2019) 20:90**

**https://doi.org/10.1186/s12882-019-1209-1**

Following publication of the original article \[[@CR1]\], the authors reported errors in the presentation of Tables [2](#Tab1){ref-type="table"}, [4](#Tab2){ref-type="table"} and [5](#Tab3){ref-type="table"}. Additionally, the authors reported an error in the last paragraph of the 'Safety assessment' section and an error in the first paragraph of the 'Discussion' section. In this Correction the incorrect and correct version of Tables [2](#Tab1){ref-type="table"}, [4](#Tab2){ref-type="table"} and [5](#Tab3){ref-type="table"} and the incorrect and correct version of the sentences in the 'Safety assessment' and 'Discussion' section are shown.

Originally Table 2 was published as: Table 2Mean Hb levels (g/dL) and mean change in hemoglobin from Baseline to EOC -- Dialysis, ITT Population (*N* = 126)StatisticsITT Population (*N* = 126)PP Population (*N* = 93)Darbepoetin alfa (*n* = 63)Erythropoietin alfa (*n* = 63)Darbepoetin alfa (*n* = 47)Erythropoietin alfa (*n* = 46)Baseline n56534746 Mean (SD)8.39 (0.90)8.80 (0.89)8.39 (0.85)8.72 (0.91)End of first evaluation visit n55514746 Mean (SD)10.20 (1.74)10.61 (1.55)10.33 (1.42)10.90 (0.95)Within group comparison *p*-value\#\<.0001\<.0001\<.0001\<.0001 Mean change1.841.851.942.18 95% CI\[1.36--2.32\]\[1.37--2.33\]\[1.48--2.40\]\[1.84--2.53\]Between group comparison Mean change−0.01−0.24 95% CI\[−0.68--0.66\]\[− 0.81--0.32\] *p*-value\*\*0.97030.3985*N* number of subject at each visit, *N* total number of subjects, *ITT* Intent to treat, *PP* Per protocol^\#^ *p*-values were obtained using Paired t Test for mean (two tailed, α 0.05)^\*\*^ *p*-values were obtained using Unpaired t Test for mean change (two tailed, α = 0.05)Note: Patients taken where Hb \< 10 at Screening

The correct version of Table [2](#Tab1){ref-type="table"}, with the corrected sections indicated in bold: Table 2Mean Hb levels (g/dL) and mean change in hemoglobin from Baseline to EOC -- Dialysis, ITT Population (*N* = 126)StatisticsITT Population (*N* = 126)PP Population (*N* = 93)Darbepoetin alfa (*n* = 63)Erythropoietin alfa (*n* = 63)Darbepoetin alfa (*n* = 47)Erythropoietin alfa (*n* = 46)Baseline n56534746 Mean (SD)8.39 (0.90)8.80 (0.89)8.39 (0.85)8.72 (0.91)End of first evaluation visit n55514746 Mean (SD)10.20 (1.74)10.61 (1.55)10.33 (1.42)10.90 (0.95)Within group comparison *p*-value^\#^\<.0001\<.0001\<.0001\<.0001 Mean change1.841.851.942.18 95% CI\[1.36--2.32\]\[1.37--2.33\]\[1.48--2.40\]\[1.84--2.53\]Between group comparison Mean change−0.01−0.24 95% CI\[−0.68--0.66\]\[− 0.81--0.32\] *p*-value^\*\*^0.97030.3985***n*** number of subject at each visit, *N* total number of subjects, *ITT* Intent to treat, *PP* Per protocol, ***Hb*** **Hemoglobin**^\#^ *p*-values were obtained using Paired t Test for mean (two tailed, **α = 0.05**)^\*\*^ *p*-values were obtained using Unpaired t Test for mean change (two tailed, α = 0.05)Note: Patients taken where Hb \< 10 at Screening

Originally Table 4 was published as: Table 4Mean change in hemoglobin levels (g/dL) from baseline to week-4StatisticsITT Population (*N* = 126)PP Population (*N* = 93)Darbepoetin alfa (*n* = 63)Erythropoietin alfa (*n* = 63)Darbepoetin alfa (*n* = 47)Erythropoietin alfa (*n* = 46)Baseline n56534746 Mean (SD)8.39 (0.90)8.80 (0.89)8.39 (0.85)8.72 (0.91)Week-4 n55504745 Mean (SD)8.66 (1.24)9.50 (1.81)8.68 (1.13)9.62 (1.71)Within group comparison *p*-value^\*^0.05660.00190.04730.0002 Mean change0.300.740.290.91 95% CI\[− 0.01--0.61\]\[0.29--1.19\]\[0.00--0.57\]\[0.45--1.36\]Between group comparison Mean change−0.44−0.62 95% CI\[−0.97--0.09\]\[−1.14--0.10\] *p*-value^\*\*^0.10570.0209*n* number of subject at each visit; *N* total number of subjects, *ITT* Intent to treat, *PP* Per protocol^\*^ *p*-value were obtained using Paired t Test for mean (two tailed, a = 0.05)^\*\*^*p*-value were obtained using Unpaired t Test for mean change (two tailed, a = 0.05)Note: Patients taken where Hb \< 10 at Screening

The correct version of Table [4](#Tab2){ref-type="table"}, with the corrected sections indicated in bold: Table 4Mean change in hemoglobin levels (g/dL) from baseline to week-4StatisticsITT Population (*N* = 126)PP Population (*N* = 93)Darbepoetin alfa (*n* = 63)Erythropoietin alfa (*n* = 63)Darbepoetin alfa (*n* = 47)Erythropoietin alfa (*n* = 46)Baseline n56534746 Mean (SD)8.39 (0.90)8.80 (0.89)8.39 (0.85)8.72 (0.91)Week-4 n55504745 Mean (SD)8.66 (1.24)9.50 (1.81)8.68 (1.13)9.62 (1.71)Within group comparison *p*-value^\*^0.05660.00190.04730.0002 Mean change0.300.740.290.91 95% CI\[− 0.01--0.61\]\[0.29--1.19\]\[0.00--0.57\]\[0.45--1.36\]Between group comparison Mean change−0.44− 0.62 95% CI\[−0.97--0.09\]\[−1.14--0.10\] ***p*-value**^**\*\***^0.10570.0209*n* number of subject at each visit; *N* total number of subjects, *ITT* Intent to treat, *PP* Per protocol, ***Hb*** **Hemoglobin**^\*^ *p*-value were obtained using Paired t Test for mean (two tailed, **α = 0.05**)^\*\*^*p*-value were obtained using Unpaired t Test for mean change (two tailed, **α = 0.05**)Note: Patients taken where Hb \< 10 at Screening

Originally Table 5 was published as: Table 5Time to initially attained target Hb level (10--12 g/dL) and proportion of patients attained target Hb level (10--12 g/dL) at EOC and EOMParameterITT Population (*N* = 126)PP Population (*N* = 93)Darbepoetin alfa (*n* = 63)Erythropoietin alfa (*n* = 63)Darbepoetin alfa (*n* = 47)Erythropoietin alfa (*n* = 46)Number of weeks to initially attain target Hb Median (95%CI)9.00 (7.00--11.00)7.00 (4.00--9.00)9.00 (7.00--10.00)7.00 (4.00--8.00)No. of Patients initially attained target Hb level N (%)44 (78.57)43 (82.69)40 (85.10)41 (89.13) Hazard Ratio (95%CI)0.807 (0.53--1.23)0.778 (0.50--1.21) *P* Value0.32120.2608No. of patients attained target Hb level at EOC N (%)33 (52.38)31 (49.2)32 (68.08)32 (69.56) Odd ratios (95%CI)0.9559 (0.46--1.99)0.9410 (0.39--2.30) *P* value0.90380.8938No. of patients maintained target Hb level at EOM  (%)24 (38.10)36 (57.14)15 (34.09)23 (57.50) Odd ratios (95%CI)0.5748 (0.26--1.25)0.4567 (0.17--1.22) *P* Value0.16210.1180*EOC* End of correction, *EOM* End of maintenance, *ITT* Intent to treat, *PP* Per protocol, *Hb* Hemoglobin

The correct version of Table [5](#Tab3){ref-type="table"}, with the corrected sections indicated in bold: Table 5Time to initially attained target Hb level (10--12 g/dL) and proportion of patients attained target Hb level (10--12 g/dL) at EOC and EOMParameterITT Population (*N* = 126)PP Population (*N* = 93)Darbepoetin alfa (*n* = 63)Erythropoietin alfa (*n* = 63)Darbepoetin alfa (*n* = 47)Erythropoietin alfa (*n* = 46)Number of weeks to initially attain target Hb Median (95%CI)9.00 (7.00--11.00)7.00 (4.00--9.00)9.00 (7.00--10.00)7.00 (4.00--8.00)No. of Patients initially attained target Hb level N (%)44 (78.57)43 (82.69)40 (85.10)41 (89.13) Hazard Ratio (95%CI)0.807 (0.53--1.23)0.778 (0.50--1.21) ***p*-value**0.32120.2608No. of patients attained target Hb level at EOC N (%)33 (52.38)31 (49.2)32 (68.08)32 (69.56) Odd ratios (95%CI)0.9559 (0.46--1.99)0.9410 (0.39--2.30)  ***p*-value**0.90380.8938No. of patients maintained target Hb level at EOM  (%)24 (38.10)36 (57.14)15 (34.09)23 (57.50) Odd ratios (95%CI)0.5748 (0.26--1.25)0.4567 (0.17--1.22)  ***p*-value**0.16210.1180*EOC* End of correction, *EOM* End of maintenance, *ITT* Intent to treat, *PP* Per protocol, *Hb* Hemoglobin

Originally the last paragraph of the 'Safety assessment' section was published as: Altogether, DA-α had a similar safety profile to that of EPO and no antibody formation was identified.

The correct presentation of the last paragraph of the 'Safety assessment' section, with the corrected words indicated in bold: Altogether, DA-α had a similar safety profile to that of EPO and no **anti-drug antibody** formation was identified.

Originally two sentences in the first paragraph of the 'Discussion' section were published as: Evaluating the iron availability for erythropoeisis is crucial in treating anaemia patients with CKD.Iron deficiency can interfere with the response to EPO and DA-α and affecting the efficacy

The correct presentation of two sentences in the first paragraph of the 'Discussion' section, with the corrected words indicated in bold: Evaluating the iron availability for erythropoeisis is crucial in treating anaemia patients with **CKD. Iron** deficiency can interfere with the response to EPO and DA-α and affecting the efficacy
